Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
University of Pittsburgh
Incyte Corporation
Merck Sharp & Dohme LLC
Incyte Corporation
Incyte Corporation
Arbeitsgemeinschaft medikamentoese Tumortherapie
University of Michigan Rogel Cancer Center
Xencor, Inc.
Exelixis
National Cancer Institute (NCI)
Fate Therapeutics
Xencor, Inc.
Ohio State University Comprehensive Cancer Center
Xencor, Inc.
Incyte Corporation
Roswell Park Cancer Institute
AbbVie
Pfizer
AbbVie
Incyte Corporation
Incyte Corporation
Gilead Sciences
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Canadian Cancer Trials Group
Swiss Cancer Institute
National Cancer Institute (NCI)
Inovio Pharmaceuticals
AbbVie
University of Kansas Medical Center
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Fox Chase Cancer Center
City of Hope Medical Center
Duke University
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)